INVO Bioscience, Inc. announced that it has entered into securities purchase agreement with new investor NAYA Biosciences, Inc. to issue 1,000,000 shares of the Company?s Series A non convertible Preferred Stock at a purchase price of $5.00 per share for the gross proceeds of $5,000,000 on December 29, 2023. The investor purchases will be made through tranches in accordance with the following schedule (1) $500,000 no later than Dec 29, 2023; (2) $500,000 no later than January 19, 2024; (3) $500,000 no later than February 2, 2024; (4) $500,000 no later than February 16, 2024; and (5) an additional amount as may be required prior to closing of the previously announced merger by and among the Company. The Company sold the Series A Preferred Stock pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9201 USD | -0.96% | -17.85% | -31.84% |
Apr. 18 | Top Premarket Decliners | MT |
Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.84% | 2.55M | |
-6.68% | 180B | |
+3.14% | 112B | |
-3.44% | 68.53B | |
+5.33% | 51.97B | |
+5.73% | 44.08B | |
+5.62% | 42.23B | |
+23.98% | 32.43B | |
+16.72% | 26.39B | |
-3.70% | 24.97B |
- Stock Market
- Equities
- INVO Stock
- News INVO Bioscience, Inc.
- INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.